<?xml version="1.0" ?><!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st June 2018//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_180601.dtd"><PubmedArticleSet><PubmedArticle>    <MedlineCitation Status="Publisher" Owner="NLM">        <PMID Version="1">30154145</PMID>        <DateRevised>            <Year>2018</Year>            <Month>08</Month>            <Day>31</Day>        </DateRevised>        <Article PubModel="Print-Electronic">            <Journal>                <ISSN IssnType="Electronic">1538-7445</ISSN>                <JournalIssue CitedMedium="Internet">                    <PubDate>                        <Year>2018</Year>                        <Month>Aug</Month>                        <Day>28</Day>                    </PubDate>                </JournalIssue>                <Title>Cancer research</Title>                <ISOAbbreviation>Cancer Res.</ISOAbbreviation>            </Journal>            <ArticleTitle>Intrathecal viral vector delivery of trastuzumab prevents or inhibits tumor growth of human HER2-positive xenografts in mice.</ArticleTitle>            <ELocationID EIdType="pii" ValidYN="Y">canres.0363.2018</ELocationID>            <ELocationID EIdType="doi" ValidYN="Y">10.1158/0008-5472.CAN-18-0363</ELocationID>            <Abstract>                <AbstractText>Breast cancer brain metastases are a deadly sequela of primary breast tumors that overexpress human epidermal growth factor receptor 2 (HER2); median survival for patients with these tumors is 10-13 months from the time of diagnosis. Current treatments for HER2-positive breast cancer brain metastases are invasive, toxic, and largely ineffective. Here we have developed an adeno-associated virus serotype 9 (AAV9) vector to express the anti-HER2 monoclonal antibody trastuzumab (Herceptin®) in vivo. A single prophylactic intrathecal administration of AAV9.trastuzumab vector in a novel orthotopic Rag1-/- murine xenograft model of HER2-positive breast cancer brain metastases significantly increased median survival, attenuated brain tumor growth, and preserved both the HER2 antigen specificity and the natural killer cell-associated mechanism of action of trastuzumab. When administered as a tumor treatment, AAV9.trastuzumab increased median survival. Dose-escalation studies revealed that higher doses of AAV9.trastuzumab resulted in smaller tumor volumes. Our results indicate that intrathecal AAV9.trastuzumab may provide significant anti-tumor activity in patients with HER2-positive breast cancer brain metastases.</AbstractText>                <CopyrightInformation>Copyright ©2018, American Association for Cancer Research.</CopyrightInformation>            </Abstract>            <AuthorList CompleteYN="Y">                <Author ValidYN="Y">                    <LastName>Rothwell</LastName>                    <ForeName>William T</ForeName>                    <Initials>WT</Initials>                    <Identifier Source="ORCID">https://orcid.org/0000-0001-5251-4714</Identifier>                    <AffiliationInfo>                        <Affiliation>Gene Therapy Program, University of Pennsylvania.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Bell</LastName>                    <ForeName>Peter</ForeName>                    <Initials>P</Initials>                    <AffiliationInfo>                        <Affiliation>University of Pennsylvania.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Richman</LastName>                    <ForeName>Laura K</ForeName>                    <Initials>LK</Initials>                    <AffiliationInfo>                        <Affiliation>University of Pennsylvania.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Limberis</LastName>                    <ForeName>Maria P</ForeName>                    <Initials>MP</Initials>                    <AffiliationInfo>                        <Affiliation>Medicine, University of Pennsylvania.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Tretiakova</LastName>                    <ForeName>Anna P</ForeName>                    <Initials>AP</Initials>                    <AffiliationInfo>                        <Affiliation>RDRU, Pfizer (United States).</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Li</LastName>                    <ForeName>Mingyao</ForeName>                    <Initials>M</Initials>                    <AffiliationInfo>                        <Affiliation>Biostatistics, Epidemiology &amp; Informatics, University of Pennsylvania.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Wilson</LastName>                    <ForeName>James M</ForeName>                    <Initials>JM</Initials>                    <AffiliationInfo>                        <Affiliation>Medicine, University of Pennsylvania wilsonjm@mail.med.upenn.edu.</Affiliation>                    </AffiliationInfo>                </Author>            </AuthorList>            <Language>eng</Language>            <PublicationTypeList>                <PublicationType UI="D016428">Journal Article</PublicationType>            </PublicationTypeList>            <ArticleDate DateType="Electronic">                <Year>2018</Year>                <Month>08</Month>                <Day>28</Day>            </ArticleDate>        </Article>        <MedlineJournalInfo>            <Country>United States</Country>            <MedlineTA>Cancer Res</MedlineTA>            <NlmUniqueID>2984705R</NlmUniqueID>            <ISSNLinking>0008-5472</ISSNLinking>        </MedlineJournalInfo>    </MedlineCitation>    <PubmedData>        <History>            <PubMedPubDate PubStatus="accepted">                <Year>2018</Year>                <Month>08</Month>                <Day>23</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="received">                <Year>2018</Year>                <Month>02</Month>                <Day>02</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="revised">                <Year>2018</Year>                <Month>07</Month>                <Day>09</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="pubmed">                <Year>2018</Year>                <Month>8</Month>                <Day>30</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="medline">                <Year>2018</Year>                <Month>8</Month>                <Day>30</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="entrez">                <Year>2018</Year>                <Month>8</Month>                <Day>30</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>        </History>        <PublicationStatus>aheadofprint</PublicationStatus>        <ArticleIdList>            <ArticleId IdType="pubmed">30154145</ArticleId>            <ArticleId IdType="pii">0008-5472.CAN-18-0363</ArticleId>            <ArticleId IdType="doi">10.1158/0008-5472.CAN-18-0363</ArticleId>        </ArticleIdList>    </PubmedData></PubmedArticle></PubmedArticleSet>